Top
Summary
All studies
Mortality
Hospitalization
Serious outcomes
Recovery
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
 
Analgesics⏵
Antiandrogens⏵
Antihistamines⏵
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Monoclonals⏵
Mpro inhibitors⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors⏵
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
 
Top
..
All NaCl studies
..
Feedback
Home
c19early.org COVID-19 treatment researchNaClNaCl (more..)
Metformin Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta Thermotherapy Meta
Melatonin Meta
Home Adoption Other Treatments
@CovidAnalysis

Outcomes in COVID-19 NaCl studies

Home
Post
Share
@CovidAnalysis
StudiesStudies
FeedbackFeedback
All studies   Mortality   Hospitalization   Serious outcomes   Recovery   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies 49% 4 492 Improvement, Studies, Patients Relative Risk Mortality 26% 1 94 Hospitalization 12% 2 138 Recovery 23% 2 135 RCTs 49% 4 492 Early 68% 3 398 Late 26% 1 94 NaCl for COVID-19 c19early.org January 2025 FavorsNaCl Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Chalageri (RCT) -200% 3.00 [0.13-69.5] hosp. 1/20 0/20 Improvement, RR [CI] Treatment Control Tanni (RCT) 75% 0.25 [0.01-6.02] hosp. 0/65 1/33 Jing (DB RCT) 71% 0.29 [0.17-0.50] OGD 14/120 56/140 OGD Tau​2​ = 0.05, I​2​ = 3.4%, p = 0.00067 Early treatment 68% 0.32 [0.17-0.62] 15/205 57/193 68% lower risk Delić (RCT) 26% 0.74 [0.53-1.03] death 22/42 37/52 Intubated patients Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.074 Late treatment 26% 0.74 [0.53-1.03] 22/42 37/52 26% lower risk All studies 49% 0.51 [0.23-1.13] 37/247 94/245 49% lower risk 4 NaCl COVID-19 studies c19early.org January 2025 Tau​2​ = 0.32, I​2​ = 68.9%, p = 0.098 Effect extraction pre-specified(most serious outcome) Favors NaCl Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Delić (RCT) 26% 0.74 [0.53-1.03] 22/42 37/52 Intubated patients Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.074 Late treatment 26% 0.74 [0.53-1.03] 22/42 37/52 26% lower risk All studies 26% 0.74 [0.53-1.03] 22/42 37/52 26% lower risk 1 NaCl COVID-19 mortality result c19early.org January 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.074 Favors NaCl Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Chalageri (RCT) -200% 3.00 [0.13-69.5] hosp. 1/20 0/20 Improvement, RR [CI] Treatment Control Tanni (RCT) 75% 0.25 [0.01-6.02] hosp. 0/65 1/33 Tau​2​ = 0.47, I​2​ = 15.4%, p = 0.92 Early treatment 12% 0.88 [0.08-9.95] 1/85 1/53 12% lower risk All studies 12% 0.88 [0.08-9.95] 1/85 1/53 12% lower risk 2 NaCl COVID-19 hospitalization results c19early.org January 2025 Tau​2​ = 0.47, I​2​ = 15.4%, p = 0.92 Favors NaCl Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Chalageri (RCT) -200% 3.00 [0.13-69.5] hosp. 1/20 0/20 Improvement, RR [CI] Treatment Control Tanni (RCT) 75% 0.25 [0.01-6.02] hosp. 0/65 1/33 Jing (DB RCT) 71% 0.29 [0.17-0.50] OGD 14/120 56/140 OGD Tau​2​ = 0.05, I​2​ = 3.4%, p = 0.00067 Early treatment 68% 0.32 [0.17-0.62] 15/205 57/193 68% lower risk Delić (RCT) 26% 0.74 [0.53-1.03] death 22/42 37/52 Intubated patients Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.074 Late treatment 26% 0.74 [0.53-1.03] 22/42 37/52 26% lower risk All studies 49% 0.51 [0.23-1.13] 37/247 94/245 49% lower risk 4 NaCl COVID-19 serious outcomes c19early.org January 2025 Tau​2​ = 0.32, I​2​ = 68.9%, p = 0.098 Effect extraction pre-specified(most serious outcome) Favors NaCl Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Chalageri (RCT) 43% 0.57 [0.42-0.78] no recov. 17 (n) 20 (n) Improvement, RR [CI] Treatment Control Tanni (RCT) -10% 1.10 [0.69-1.72] no recov. 65 (n) 33 (n) Tau​2​ = 0.17, I​2​ = 81.6%, p = 0.44 Early treatment 23% 0.77 [0.41-1.47] 82 (n) 53 (n) 23% lower risk All studies 23% 0.77 [0.41-1.47] 82 (n) 53 (n) 23% lower risk 2 NaCl COVID-19 recovery results c19early.org January 2025 Tau​2​ = 0.17, I​2​ = 81.6%, p = 0.44 Favors NaCl Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Chalageri (RCT) -200% 3.00 [0.13-69.5] hosp. 1/20 0/20 Improvement, RR [CI] Treatment Control Tanni (RCT) 75% 0.25 [0.01-6.02] hosp. 0/65 1/33 Jing (DB RCT) 71% 0.29 [0.17-0.50] OGD 14/120 56/140 OGD Tau​2​ = 0.05, I​2​ = 3.4%, p = 0.00067 Early treatment 68% 0.32 [0.17-0.62] 15/205 57/193 68% lower risk Delić (RCT) 26% 0.74 [0.53-1.03] death 22/42 37/52 Intubated patients Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.074 Late treatment 26% 0.74 [0.53-1.03] 22/42 37/52 26% lower risk All studies 49% 0.51 [0.23-1.13] 37/247 94/245 49% lower risk 4 NaCl COVID-19 Randomized Controlled Trials c19early.org January 2025 Tau​2​ = 0.32, I​2​ = 68.9%, p = 0.098 Effect extraction pre-specified(most serious outcome) Favors NaCl Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Delić (RCT) 26% 0.74 [0.53-1.03] 22/42 37/52 Intubated patients Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.074 Late treatment 26% 0.74 [0.53-1.03] 22/42 37/52 26% lower risk All studies 26% 0.74 [0.53-1.03] 22/42 37/52 26% lower risk 1 NaCl COVID-19 RCT mortality result c19early.org January 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.074 Favors NaCl Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Chalageri (RCT) -200% 3.00 [0.13-69.5] hosp. 1/20 0/20 Improvement, RR [CI] Treatment Control Tanni (RCT) 75% 0.25 [0.01-6.02] hosp. 0/65 1/33 Jing (DB RCT) 71% 0.29 [0.17-0.50] OGD 14/120 56/140 OGD Tau​2​ = 0.05, I​2​ = 3.4%, p = 0.00067 Early treatment 68% 0.32 [0.17-0.62] 15/205 57/193 68% lower risk Delić (RCT) 26% 0.74 [0.53-1.03] death 22/42 37/52 Intubated patients Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.074 Late treatment 26% 0.74 [0.53-1.03] 22/42 37/52 26% lower risk All studies 49% 0.51 [0.23-1.13] 37/247 94/245 49% lower risk 4 NaCl COVID-19 peer reviewed studies c19early.org January 2025 Tau​2​ = 0.32, I​2​ = 68.9%, p = 0.098 Effect extraction pre-specified(most serious outcome) Favors NaCl Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Chalageri (RCT) -200% 3.00 [0.13-69.5] hosp. 1/20 0/20 Improvement, RR [CI] Treatment Control Chalageri (RCT) 43% 0.57 [0.42-0.78] no recov. 17 (n) 20 (n) Tanni (RCT) 75% 0.25 [0.01-6.02] hosp. 0/65 1/33 Tanni (RCT) -10% 1.10 [0.69-1.72] no recov. 65 (n) 33 (n) Tanni (RCT) 52% 0.48 [0.27-0.83] no recov. 65 (n) 33 (n) Tanni (RCT) 33% 0.67 [0.41-1.10] no recov. 65 (n) 33 (n) Tanni (RCT) 2% 0.98 [0.62-1.54] no recov. 65 (n) 33 (n) Tanni (RCT) -9% 1.09 [0.68-1.72] no recov. 65 (n) 33 (n) Jing (DB RCT) 71% 0.29 [0.17-0.50] OGD 14/120 56/140 OGD Jing (DB RCT) 97% 0.03 [0.00-0.57] severe case 0/120 15/140 Jing (DB RCT) 95% 0.05 [0.00-0.78] severe case 0/120 11/140 Jing (DB RCT) 93% 0.07 [0.01-0.62] severe case 0/120 7/140 Delić (RCT) 26% 0.74 [0.53-1.03] death 22/42 37/52 Intubated patients Delić (RCT) 32% 0.68 [0.44-1.04] death 17/42 31/52 Intubated patients NaCl COVID-19 outcomes c19early.org January 2025 Favors NaCl Favors control
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0